Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America
Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western...
Saved in:
| Published in | PloS one Vol. 10; no. 12; p. e0145380 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
30.12.2015
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA).
Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled.
Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001).
In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. |
|---|---|
| AbstractList | Objectives Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Design and Methods Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Results Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included [greater than or equal to]3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). Conclusions In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA).Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled.Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001).In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included [greater than or equal to]3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. Objectives: rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Design and methods: between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Results: significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). Conclusions: in EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. Objectives Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Design and Methods Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Results Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00–4.09), prior anti-TB treatment (3.42 (1.88–6.22)), and living in EE (7.19 (3.28–15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90–96% in other regions (p<0.0001). Conclusions In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. OBJECTIVESRates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA).DESIGN AND METHODSBetween January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled.RESULTSSignificant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001).CONCLUSIONSIn EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. |
| Audience | Academic |
| Author | Miller, Robert F Miro, Jose M Efsen, Anne Marie W Mocroft, Amanda Panteleev, Alexander Furrer, Hansjakob Lundgren, Jens D Caylà, Joan A Post, Frank A Toibaro, Javier Podlekareva, Daria N Girardi, Enrico Schultze, Anna Losso, Marcelo H Obel, Niels Skrahin, Aliaksandr Kirk, Ole Bruyand, Mathias |
| AuthorAffiliation | 3 Department of Sexual Health, Caldecot Centre, King's College Hospital, London, United Kingdom 8 Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus 10 Agencia de Salud Pública de Barcelona, Barcelona, España; Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain 12 INSERM, ISPED, Centre Inserm U897- Epidemiologie-Biostatistique, Bordeaux, France 7 Department of immunocompromised, Hospital J.M. Ramos Mejia, Buenos Aires, Argentina 2 Department of Infection and Population Health, University College London Medical School, London, United Kingdom 13 Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 4 Department of HIV/TB, TB hospital 2, St. Petersburg, Russia 5 Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Swi |
| AuthorAffiliation_xml | – name: 4 Department of HIV/TB, TB hospital 2, St. Petersburg, Russia – name: 10 Agencia de Salud Pública de Barcelona, Barcelona, España; Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain – name: 1 Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – name: 6 Centre for Sexual Health and HIV Research, Mortimer Market Centre, University College London, London, United Kingdom – name: 5 Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland – name: 7 Department of immunocompromised, Hospital J.M. Ramos Mejia, Buenos Aires, Argentina – name: 3 Department of Sexual Health, Caldecot Centre, King's College Hospital, London, United Kingdom – name: 11 Department of Infectious Diseases INMI "L. Spallanzani", Ospedale L Spallanzani, Rome, Italy – name: 9 Infectious Diseases Service, Hospital Clinic–IDIBAPS. University of Barcelona, Barcelona, Spain – name: 12 INSERM, ISPED, Centre Inserm U897- Epidemiologie-Biostatistique, Bordeaux, France – name: 2 Department of Infection and Population Health, University College London Medical School, London, United Kingdom – name: 13 Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – name: FIOCRUZ, BRAZIL – name: 8 Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus |
| Author_xml | – sequence: 1 givenname: Anne Marie W surname: Efsen fullname: Efsen, Anne Marie W organization: Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 2 givenname: Anna surname: Schultze fullname: Schultze, Anna organization: Department of Infection and Population Health, University College London Medical School, London, United Kingdom – sequence: 3 givenname: Frank A surname: Post fullname: Post, Frank A organization: Department of Sexual Health, Caldecot Centre, King's College Hospital, London, United Kingdom – sequence: 4 givenname: Alexander surname: Panteleev fullname: Panteleev, Alexander organization: Department of HIV/TB, TB hospital 2, St. Petersburg, Russia – sequence: 5 givenname: Hansjakob surname: Furrer fullname: Furrer, Hansjakob organization: Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland – sequence: 6 givenname: Robert F surname: Miller fullname: Miller, Robert F organization: Centre for Sexual Health and HIV Research, Mortimer Market Centre, University College London, London, United Kingdom – sequence: 7 givenname: Marcelo H surname: Losso fullname: Losso, Marcelo H organization: Department of immunocompromised, Hospital J.M. Ramos Mejia, Buenos Aires, Argentina – sequence: 8 givenname: Javier surname: Toibaro fullname: Toibaro, Javier organization: Department of immunocompromised, Hospital J.M. Ramos Mejia, Buenos Aires, Argentina – sequence: 9 givenname: Aliaksandr surname: Skrahin fullname: Skrahin, Aliaksandr organization: Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus – sequence: 10 givenname: Jose M surname: Miro fullname: Miro, Jose M organization: Infectious Diseases Service, Hospital Clinic-IDIBAPS. University of Barcelona, Barcelona, Spain – sequence: 11 givenname: Joan A surname: Caylà fullname: Caylà, Joan A organization: Agencia de Salud Pública de Barcelona, Barcelona, España; Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain – sequence: 12 givenname: Enrico surname: Girardi fullname: Girardi, Enrico organization: Department of Infectious Diseases INMI "L. Spallanzani", Ospedale L Spallanzani, Rome, Italy – sequence: 13 givenname: Mathias surname: Bruyand fullname: Bruyand, Mathias organization: INSERM, ISPED, Centre Inserm U897- Epidemiologie-Biostatistique, Bordeaux, France – sequence: 14 givenname: Niels surname: Obel fullname: Obel, Niels organization: Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 15 givenname: Daria N surname: Podlekareva fullname: Podlekareva, Daria N organization: Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 16 givenname: Jens D surname: Lundgren fullname: Lundgren, Jens D organization: Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 17 givenname: Amanda surname: Mocroft fullname: Mocroft, Amanda organization: Department of Infection and Population Health, University College London Medical School, London, United Kingdom – sequence: 18 givenname: Ole surname: Kirk fullname: Kirk, Ole organization: Centre for Health and Infectious Disease Research (CHIP), Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26716686$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk1tv0zAUxyM0xC7wDRBEQkLw0M7XXF6QSjVYpU5DMMaj5dhO6sqxi51w-QJ8btw2qxa0BxRFTo5___-Jz8k5TY6ssypJnkMwhTiH52vXe8vNdBPDUwAJxQV4lJzAEqNJhgA-uvd8nJyGsAYgMln2JDlGWQ6zrMhOkj9XfO18Ol9xY5RtVEi1TedGWy24Sa-45Y1qle1SV6c3788vF7fp3GlbK9EpmX7inY6bO9EFD53yce2926hItRvuI_NTd6v0mxptcivTZdTadNYqH1M9TR7X3AT1bFjPkq8fLm7ml5Pl9cfFfLaciByTbgKprKSoSAmLqgQFQRTXVSYFJULUsBBAgYqgSkIkKaxlhRUWVU1qCiGpOUT4LHm5990YF9hQwsBgThEtMKIwEos9IR1fs43XLfe_meOa7QLON4z7TgujGKEIYxJdCS9JXcGSc4QQoEQiACTZZns3ZOurVkkRS-W5GZmOd6xescb9YCQrY3eyaAD3BiL0gnkllBe82wkPL9sbgRwxlKESg6h5MyT17nsf685aHYQyhlvl-t1ZMSGElmVEX_2DPlyRgWp4PHTsvYvfKrambEZwkaOcZnmkpg9Q8ZKq1SL-o7WO8ZHg7UgQmU796hreh8AWXz7_P3t9O2Zf32NXiptuFZzpO-1sGINkKK53IXhVHxoDAduO2F012HbE2DBiUfbiflMPoruZwn8BqdAh_g |
| CitedBy_id | crossref_primary_10_1186_s12879_018_3077_x crossref_primary_10_1183_13993003_02363_2016 crossref_primary_10_1111_hiv_13163 crossref_primary_10_21101_cejph_a4950 crossref_primary_10_1093_ofid_ofz233 crossref_primary_10_1556_1886_2021_00021 crossref_primary_10_1016_S2352_3018_15_00252_0 crossref_primary_10_22328_2077_9828_2019_11_4_70_78 crossref_primary_10_1016_S0140_6736_20_31316_7 crossref_primary_10_1016_j_jinf_2017_10_007 crossref_primary_10_1097_QCO_0000000000000326 crossref_primary_10_1371_journal_pone_0282046 crossref_primary_10_1097_QAD_0000000000001333 crossref_primary_10_1371_journal_pone_0256531 crossref_primary_10_1016_S0140_6736_16_30856_X crossref_primary_10_1186_s12879_019_4317_4 crossref_primary_10_1097_QAD_0000000000003670 crossref_primary_10_3389_fpubh_2023_1241042 crossref_primary_10_1097_QCO_0000000000000704 |
| Cites_doi | 10.1001/jama.300.4.423 10.1056/NEJMoa0907847 10.1183/09031936.00145411 10.1371/journal.pmed.1001510 10.1056/NEJMra1200894 10.1056/NEJMoa1005136 10.1097/QAD.0b013e3283326879 10.1371/journal.pone.0015735 10.1016/S0140-6736(10)60232-2 10.1183/09031936.00003710 10.1016/j.jinf.2013.09.034 10.1016/j.drugpo.2013.09.001 10.1196/annals.1425.009 10.1007/s11904-014-0202-3 10.1136/thx.2005.045963 10.7448/IAS.17.4.19505 10.1038/ng.2878 10.1056/NEJMra0908076 10.1016/S1473-3099(13)70030-6 10.1371/journal.pmed.1001270 10.1016/j.drugpo.2006.12.014 10.1086/522537 10.1016/S2213-2600(14)70031-1 10.1016/S0140-6736(12)60734-X |
| ContentType | Journal Article |
| Contributor | Universitat de Barcelona |
| Contributor_xml | – sequence: 1 fullname: Universitat de Barcelona |
| Copyright | COPYRIGHT 2015 Public Library of Science 2015 Efsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. cc-by (c) Efsen, Anne Marie W. et al., 2015 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/3.0/es 2015 Efsen et al 2015 Efsen et al |
| Copyright_xml | – notice: COPYRIGHT 2015 Public Library of Science – notice: 2015 Efsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: cc-by (c) Efsen, Anne Marie W. et al., 2015 info:eu-repo/semantics/openAccess <a href="http://creativecommons.org/licenses/by/3.0/es">http://creativecommons.org/licenses/by/3.0/es</a> – notice: 2015 Efsen et al 2015 Efsen et al |
| CorporateAuthor | TB:HIV study group in EuroCoord |
| CorporateAuthor_xml | – sequence: 0 name: TB:HIV study group in EuroCoord – name: TB:HIV study group in EuroCoord |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PIMPY PQEST PQQKQ PQUKI PTHSS PYCSY RC3 7X8 XX2 5PM DOA |
| DOI | 10.1371/journal.pone.0145380 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Opposing Viewpoints in Context (Gale) Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database (ProQuest) Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic Recercat PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic Technology Collection Technology Research Database Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Agricultural Science Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | TB/HIV Patients in Eastern Europe |
| EISSN | 1932-6203 |
| Editor | Pacheco, Antonio Guilherme |
| Editor_xml | – sequence: 1 givenname: Antonio Guilherme surname: Pacheco fullname: Pacheco, Antonio Guilherme |
| EndPage | e0145380 |
| ExternalDocumentID | 1752583251 oai_doaj_org_article_4523341234a94fb19aa222054d200d42 oai_recercat_cat_2072_262930 3908386821 A438727567 10_1371_journal_pone_0145380 26716686 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Observational Study |
| GeographicLocations | Europe, Eastern Europe Latin America Eastern Europe Western Europe |
| GeographicLocations_xml | – name: Europe, Eastern – name: Latin America – name: Europe – name: Eastern Europe – name: Western Europe |
| GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BBORY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CGR CS3 CUY CVF D1I D1J D1K DIK DU5 E3Z EAP EAS EBD ECM EIF EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ NPM O5R O5S OK1 P2P P62 PATMY PDBOC PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RIG RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM AAYXX CITATION AFPKN 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PQEST PQUKI RC3 7X8 XX2 5PM - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c734t-15dbdcb4918b9084253fb6dc54ccf18c0e0b42bd12d51fdb3e3cbf4f5114fa123 |
| IEDL.DBID | RPM |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:12:32 EST 2021 Tue Oct 22 15:14:06 EDT 2024 Tue Sep 17 21:29:15 EDT 2024 Fri Dec 13 12:17:45 EST 2024 Fri Oct 25 04:41:13 EDT 2024 Wed Nov 20 16:46:11 EST 2024 Tue Nov 19 21:04:47 EST 2024 Tue Nov 12 23:32:25 EST 2024 Thu Aug 01 20:35:54 EDT 2024 Thu Aug 01 19:35:00 EDT 2024 Tue Aug 20 22:05:53 EDT 2024 Fri Dec 06 05:20:04 EST 2024 Tue Oct 15 23:55:22 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c734t-15dbdcb4918b9084253fb6dc54ccf18c0e0b42bd12d51fdb3e3cbf4f5114fa123 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Conceived and designed the experiments: AWE ASC AM DNP JDL OK. Performed the experiments: AWE ASC AM DNP JDL OK. Analyzed the data: AWE ASC AM DNP JDL OK FP AP HF RM MHL JT ASK JMM JAC EG MB NO. Contributed reagents/materials/analysis tools: AWE ASC AM DNP JDL OK FP AP HF RM MHL JT ASK JMM JAC EG MB NO. Wrote the paper: AWE ASC AM DNP JDL OK FP AP HF RM MHL JT ASK JMM JAC EG MB NO. Performed statistical analyses: ASC AM. Competing Interests: AMW reports a personal grant from University Hospital Copenhagen. AS reports grants and travel support from University College London. HF reports consultancy fees from ViiV, Gilead, Abbvie, MSD, Jannsen, BMS and grants from ViiV, Gilead, AbbVie, Roche, Boehringer, MSD, BMS, Janssen outside the submitted work. RM reports payment for lectures from ViiV, Merck, Gilead and Janssen outside the submitted work. JMM reports consultancy fees from Abbvie, Novartis, payment for lectures from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck and Novartis y ViiV Healthcare and grants from Cubist, Gilead, ViiV Healthcare, Novartis, Merck, Fondo de Investigaciones Sanitarias - Instituto de Salud Carlos III, Fundación para la Investigación y Prevención del Sida en España, Ministerio de Sanidad, Servicios Sociales e Igualdad, National Institutes of Health and NEAT outside the submitted work. EG reports board membership for Janssen-Cilag, consultancy fees from Abbot-Diagnostics, payment for lectures from BMS, ViiV Healthcare, Jannsen and grants from Gilead Sciences outside the submitted work. JT reports grants from EuroCoord and University of Buenos Aires, CICAL during conduct of the study. MHL reports grants from EuroCoord, employment from University of Buenos Aires, Hospital JM Ramos Mejia, CICAL and grants from NIH, University of Minnesota, University of New South Wales, travel fees from Gador outside the submitted work. AM reports speaker fees, travel fees and honorarium from BI, Gilead, Pfizer, Merck and BMS outside the submitted work. OK reports board membership from Gilead, Merck, ViiV, consultancy fees from Gilead, payment for lectures from Abbott, Gilead, Tibotec, travel fees from Abbott, BMS, Gilead, Merck, ViiV and grants from Bristol-Myers Squibb, Janssen, Merck, Pfizer, GlaxoSmithKline outside the submitted work. For the remaining authors, none were declared. Although several authors have received grants, honoraria or travel support from a number of pharmaceutical companies, none have declared a conflict of interest in relation to the work presented in this manuscript. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Membership of the TB:HIV Study Group investigators is provided in the Acknowledgements. |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696866/ |
| PMID | 26716686 |
| PQID | 1752583251 |
| PQPubID | 1436336 |
| PageCount | 17 |
| ParticipantIDs | plos_journals_1752583251 doaj_primary_oai_doaj_org_article_4523341234a94fb19aa222054d200d42 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4696866 csuc_recercat_oai_recercat_cat_2072_262930 proquest_miscellaneous_1753444599 proquest_journals_1752583251 gale_infotracmisc_A438727567 gale_infotracacademiconefile_A438727567 gale_incontextgauss_ISR_A438727567 gale_incontextgauss_IOV_A438727567 gale_healthsolutions_A438727567 crossref_primary_10_1371_journal_pone_0145380 pubmed_primary_26716686 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-12-30 |
| PublicationDateYYYYMMDD | 2015-12-30 |
| PublicationDate_xml | – month: 12 year: 2015 text: 2015-12-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2015 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – sequence: 0 name: Public Library of Science (PLoS) – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | 20825313 - N Engl J Med. 2010 Sep 9;363(11):1005-15 24717628 - Lancet Respir Med. 2014 Apr;2(4):321-38 24652411 - Curr HIV/AIDS Rep. 2014 Jun;11(2):168-76 22938757 - Lancet. 2012 Oct 20;380(9851):1406-17 17954675 - Ann N Y Acad Sci. 2008;1136:1-11 20825317 - N Engl J Med. 2010 Sep 9;363(11):1050-8 22911011 - PLoS Med. 2012;9(7):e1001270 22005924 - Eur Respir J. 2012 Jun;39(6):1425-31 19898216 - AIDS. 2009 Nov 27;23(18):2485-95 23531391 - Lancet Infect Dis. 2013 Jun;13(6):529-39 25394014 - J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19505 17689374 - Int J Drug Policy. 2007 Aug;18(4):262-70 21209951 - PLoS One. 2010;5(12):e15735 20189638 - Lancet. 2010 Mar 20;375(9719):1014-28 25959854 - HIV Med. 2015 Oct;16(9):544-52 24247067 - J Infect. 2014 Mar;68(3):259-63 24137103 - PLoS Med. 2013;10(9):e1001510 21732833 - N Engl J Med. 2011 Jul 7;365(1):11-20 18647985 - JAMA. 2008 Jul 23;300(4):423-30 23425167 - N Engl J Med. 2013 Feb 21;368(8):745-55 20185428 - Eur Respir J. 2010 Sep;36(3):584-93 17968823 - Clin Infect Dis. 2007 Nov 15;45(10):1290-5 24464101 - Nat Genet. 2014 Mar;46(3):279-86 24360402 - Int J Drug Policy. 2013 Nov;24(6):e91-8 16254056 - Thorax. 2006 Feb;61(2):158-63 V Leimane (ref13) 2010; 36 BM Mathers (ref29) 2010; 375 FA Post (ref14) 2014; 68 CC Boehme (ref24) 2010; 363 ref31 HR Kim (ref28) 2007; 45 ref33 O Morozova (ref34) 2013; 24 I Abubakar (ref8) 2013; 13 ref10 DN Podlekareva (ref15) 2009; 23 ref2 DV Havlir (ref5) 2008; 300 E Nathanson (ref9) 2010; 363 K Dheda (ref12) 2014; 2 ref17 A Skrahina (ref6) 2012; 39 J DeHovitz (ref1) 2014; 11 A Zumla (ref7) 2013; 368 M Mansfeld (ref22) 2015 A Faustini (ref21) 2006; 61 ref23 S Keshavjee (ref18) 2008; 1136 ref26 ref25 T Dalton (ref20) 2012; 380 B Spire (ref35) 2007; 18 A Mocroft (ref3) 2013; 10 JR Andrews (ref19) 2010; 5 ref27 AM Efsen (ref16) 2014; 17 NA Martinson (ref30) 2011; 365 AB Suthar (ref32) 2012; 9 ref4 N Casali (ref11) 2014; 46 |
| References_xml | – volume: 300 start-page: 423 issue: 4 year: 2008 ident: ref5 article-title: Opportunities and challenges for HIV care in overlapping HIV and TB epidemics publication-title: JAMA: the journal of the American Medical Association doi: 10.1001/jama.300.4.423 contributor: fullname: DV Havlir – volume: 363 start-page: 1005 issue: 11 year: 2010 ident: ref24 article-title: Rapid molecular detection of tuberculosis and rifampin resistance publication-title: N Engl J Med doi: 10.1056/NEJMoa0907847 contributor: fullname: CC Boehme – volume: 39 start-page: 1425 issue: 6 year: 2012 ident: ref6 article-title: Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk publication-title: The European respiratory journal doi: 10.1183/09031936.00145411 contributor: fullname: A Skrahina – volume: 10 start-page: e1001510 issue: 9 year: 2013 ident: ref3 article-title: Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) publication-title: PLoS Med doi: 10.1371/journal.pmed.1001510 contributor: fullname: A Mocroft – volume: 368 start-page: 745 issue: 8 year: 2013 ident: ref7 article-title: Tuberculosis publication-title: The New England journal of medicine doi: 10.1056/NEJMra1200894 contributor: fullname: A Zumla – volume: 365 start-page: 11 issue: 1 year: 2011 ident: ref30 article-title: New regimens to prevent tuberculosis in adults with HIV infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1005136 contributor: fullname: NA Martinson – volume: 23 start-page: 2485 issue: 18 year: 2009 ident: ref15 article-title: Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina publication-title: AIDS doi: 10.1097/QAD.0b013e3283326879 contributor: fullname: DN Podlekareva – volume: 5 start-page: e15735 issue: 12 year: 2010 ident: ref19 article-title: Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community publication-title: PloS one doi: 10.1371/journal.pone.0015735 contributor: fullname: JR Andrews – volume: 375 start-page: 1014 issue: 9719 year: 2010 ident: ref29 article-title: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage publication-title: Lancet doi: 10.1016/S0140-6736(10)60232-2 contributor: fullname: BM Mathers – volume: 36 start-page: 584 issue: 3 year: 2010 ident: ref13 article-title: Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004 publication-title: The European respiratory journal doi: 10.1183/09031936.00003710 contributor: fullname: V Leimane – year: 2015 ident: ref22 article-title: Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe publication-title: HIV medicine contributor: fullname: M Mansfeld – ident: ref25 – ident: ref27 – volume: 68 start-page: 259 issue: 3 year: 2014 ident: ref14 article-title: Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe publication-title: J Infect doi: 10.1016/j.jinf.2013.09.034 contributor: fullname: FA Post – volume: 24 start-page: e91 issue: 6 year: 2013 ident: ref34 article-title: Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine publication-title: The International journal on drug policy doi: 10.1016/j.drugpo.2013.09.001 contributor: fullname: O Morozova – volume: 1136 start-page: 1 year: 2008 ident: ref18 article-title: Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease publication-title: Annals of the New York Academy of Sciences doi: 10.1196/annals.1425.009 contributor: fullname: S Keshavjee – volume: 11 start-page: 168 issue: 2 year: 2014 ident: ref1 article-title: The HIV Epidemic in Eastern Europe and Central Asia publication-title: Current HIV/AIDS reports doi: 10.1007/s11904-014-0202-3 contributor: fullname: J DeHovitz – volume: 61 start-page: 158 issue: 2 year: 2006 ident: ref21 article-title: Risk factors for multidrug resistant tuberculosis in Europe: a systematic review publication-title: Thorax doi: 10.1136/thx.2005.045963 contributor: fullname: A Faustini – volume: 17 start-page: 19505 issue: 4 Suppl 3 year: 2014 ident: ref16 article-title: Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America publication-title: J Int AIDS Soc doi: 10.7448/IAS.17.4.19505 contributor: fullname: AM Efsen – ident: ref17 – ident: ref4 – ident: ref2 – volume: 46 start-page: 279 issue: 3 year: 2014 ident: ref11 article-title: Evolution and transmission of drug-resistant tuberculosis in a Russian population publication-title: Nature genetics doi: 10.1038/ng.2878 contributor: fullname: N Casali – volume: 363 start-page: 1050 issue: 11 year: 2010 ident: ref9 article-title: MDR tuberculosis—critical steps for prevention and control publication-title: The New England journal of medicine doi: 10.1056/NEJMra0908076 contributor: fullname: E Nathanson – volume: 13 start-page: 529 issue: 6 year: 2013 ident: ref8 article-title: Drug-resistant tuberculosis: time for visionary political leadership publication-title: The Lancet infectious diseases doi: 10.1016/S1473-3099(13)70030-6 contributor: fullname: I Abubakar – ident: ref23 – volume: 9 start-page: e1001270 issue: 7 year: 2012 ident: ref32 article-title: Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis publication-title: PLoS Med doi: 10.1371/journal.pmed.1001270 contributor: fullname: AB Suthar – ident: ref26 – volume: 18 start-page: 262 issue: 4 year: 2007 ident: ref35 article-title: Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST) publication-title: The International journal on drug policy doi: 10.1016/j.drugpo.2006.12.014 contributor: fullname: B Spire – volume: 45 start-page: 1290 issue: 10 year: 2007 ident: ref28 article-title: Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clinical infectious diseases: an official publication of the publication-title: Infectious Diseases Society of America doi: 10.1086/522537 contributor: fullname: HR Kim – volume: 2 start-page: 321 issue: 4 year: 2014 ident: ref12 article-title: Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis publication-title: The lancet Respiratory medicine doi: 10.1016/S2213-2600(14)70031-1 contributor: fullname: K Dheda – ident: ref10 – volume: 380 start-page: 1406 issue: 9851 year: 2012 ident: ref20 article-title: Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(12)60734-X contributor: fullname: T Dalton – ident: ref33 – ident: ref31 |
| SSID | ssj0053866 |
| Score | 2.3733625 |
| Snippet | Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors... Objectives Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics,... OBJECTIVESRates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics,... Objectives: rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics,... Objectives Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics,... |
| SourceID | plos doaj pubmedcentral csuc proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0145380 |
| SubjectTerms | Adult Amèrica Llatina Analysis Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral therapy Antitubercular Agents - therapeutic use Care and treatment Coinfection - drug therapy Collaboration Comorbidity Diagnosis Drug resistance Drug therapy Drugs Eastern Europe Europa de l'Est Europa Occidental Europe Europe, Eastern Female Hepatitis Highly active antiretroviral therapy HIV HIV (Viruses) HIV infections HIV Infections - drug therapy Hospitals Human immunodeficiency virus Humans Infeccions per VIH Infections Infectious diseases Latin America Male Medical diagnosis Middle Aged Mortality Multidrug resistance Multidrug resistant organisms Narcotics Patients Prospective Studies Resistència als medicaments Rheumatology Risk Factors Studies Substance abuse treatment Systematic review Terapèutica Therapeutics Therapy Tuberculosi Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy VIH (Virus) Western Europe |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquhBQxC4iGlTWzHSY7tqtUWUUDQlt4sP6GoSlab3b_A72Yce8MGVYIDhz3szjjSzjcej-OZzwi95EZzbfMqdRVTKSuVS6VUZcokcbJSVjHqG4VPP_DZOXt3WVxuXPXla8ICPXAw3D6DnRJEWkKZrJlTeS0l8c2hzAC-hoXom5H1ZirEYJjFnMdGOVrm-xGXvXnb2D1_kEY9DeTGQjTR3UpH2v4hOE_m1213U-b5ZwHlxop0fBfdiakkPgh_YQvdss09tBUna4dfR0bpN_fRz1P5o13g6frilA5fNTgygl7j3xUwuHX47HB_dnKBp20o07IGfwrUq_2gI9kTK-DwEh9PYwU79q9z8Vc7EsrG4PcwtsHxWOgBOj8-OpvO0ngBQ6pLypZpXhhltGJ1Xqk68wd21ClAt2Bau7zSmc0UI8rkxBS5M4paqpVjDpI45iRg9hBNGjD5NsJVaUuTAXyO9GFDVgCe4pQaqyEFYglK12iIeeDZEP1hWwn7k2BP4dETEb0EvfWQCVgW7ELLpfA02cMX_yFZSQThkM6A8qEHdniw1-1_AEcT0dHE3xwtQc-8W4jQnzoEBnHAaFV6Ev0yQS96DU-r0fi6nW9y1XXi5OPFPyh9-TxSehWVXAsOpmXslQADeLqukebuSBOCgx6Jt70Tr03YCcgWSQFRvMhh5NqxbxY_H8T-ob4Wr7HtqtehjLGirhP0KMyDwbKEw_6bVzxB5WiGjEw_ljRX33tWc-Zpmjh__D-w2kG3IbEtekLObBdNlouVfQLJ41I97ePEL0x_as4 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLagvPCCGLcFBhiExEXKmtiOkzyhrVrpEAMEu71Zvo6hKSlN-xf43fgkTregCfHQh_QcR9G52z7-jNArbjTXNi1iVzAVs1y5WEqVx0wSJwtlFaNwUPjgM58dsY-n2WlYcGtCW2UfE9tAbWoNa-Rjn-ZI5s0vS9_Pf8VwaxTsroYrNG6iWynJObT0FdMPfST2vsx5OC5H83QctLM9ryu7DdtpFMAgr6SjkW5WOoD3r0P0aH5RN9fVn3-3UV7JS9O76E4oKPFOZwEb6Iat7qGN4LINfhNwpd_eR78P5M96gSf99SkNPq9wwAW9wJd9MLh2-HB3PNs_xpO6a9ayBn_tAFjbQXuyhVfA3VI-noQ-dgyLuvjEDoiyMviTH1vhsDn0AB1N9w4nszhcwxDrnLJlnGZGGa1YmRaqTGDbjjrldZwxrV1a6MQmihFlUmKy1BlFLdXKMedLOeakz4wP0ajyIt9EuMhtbhKVlo60wUMWiWGKU2qs9oUQi1Dca0PMO7QN0W655X6W0slTgPZE0F6E3oHKhE8OdqHlUgBY9voBfiTJiSDcFzWeeRcUu34x8LZ_1IszEfxUMD8x94mdUCZL5vyXSkngLDIzPpwYRiL0HMxCdKdU1-FB7DBa5ACln0foZcsB4BoVdO-cyVXTiP0vx__B9P3bgOl1YHK1NzAtw4kJLwAA7Rpwbg04fYjQA_ImGHEvwkZcOpMf2Rv29eQXazK8FDryKluvWh7KGMvKMkKPOj9YS5ZwPwvnBY9QPvCQgeiHlOr8R4ttzgCsifPH__6sJ-i2L1yzFnAz2UKj5WJln_ricKmetRHgD1FhZFk priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9NAEF5V4YUXRLlqKLAgJA7Jxcf6ekCojVqliACCpvRttWcpiuwQJxL8AX43M_ba1CiVePBDPLOraHau9c58S8izVKtUmTD3bc6kzzJpfSFk5jMRWZFLI1mMjcLTD-lkxt6dJWdbpLuz1Qmw3ri1w_ukZsv53s8fv96Cwb9pbm3Iwm7Q3qIqzR4ek8U5bOKvRRAbschryvpzBaCkqWugu2okwgOnsItIsb36UqwaqXqtHLJ_779Hi3lVb0pO_62xvBS0jm6SGy7bpPutemyTLVPeItvOnmv6woFOv7xNfk_F92pJx93dKjW9KKkDDZ3Tv0UytLL05OD15PiUjqu2ksto-qlFZ20GHYoGe4G23_np2BW5U_ziS7-aAVGUmr6HsSV1J0d3yOzo8GQ88d0dDb7KYrbyw0RLrSQrwlwWAZ7pxVaCAiRMKRvmKjCBZJHUYaST0GoZm1hJyyzkecwKCJt3yagE6e8Qmmcm04EMCxs1nkXkgWYyjWNtFGRJzCN-txp80UJx8OY8LoMtTCtPjgvJ3UJ65BUuGYfIYZZKrDgiafc_8ImCLOJRChkPMB_gwvYTI2_zolqec2fEnMGuHaJ-FDNRMAv_VIgIG5WZBl-jWeSRx6gWvG1h7X0H32dxniHOfuaRpw0HIm-UWNpzLtZ1zY8_nv4H05fPA6bnjslWoGBKuHYKEAAieg04dwec4D_UgLyDStyJsOaQUEYJOPokhJGdYm8mP-nJOCmW65WmWjc8MWMsKQqP3GvtoJdsZ1weyQYWMhD9kFJefGuAzxkiOaXp_SvnfECuQ0KbNECcwS4ZrZZr8xCSxpV81PiBPwVeaho priority: 102 providerName: Scholars Portal |
| Title | Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26716686 https://www.proquest.com/docview/1752583251 https://search.proquest.com/docview/1753444599 https://recercat.cat/handle/2072/262930 https://pubmed.ncbi.nlm.nih.gov/PMC4696866 https://doaj.org/article/4523341234a94fb19aa222054d200d42 http://dx.doi.org/10.1371/journal.pone.0145380 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZbxMxELba8MILolxdKMEgJA5pkz28Rx6bKCVFpESlLXmzfJagdDfKJn-B383Y6w1d1AfEQyxlPV6tZjyH7ZnPCL1NpUiFCnNf54T7JOPaZ4xnPmGRZjlXnMSmUHh6lk4uyed5Mt9DSVMLY5P2BV_0iuVNr1j8sLmVqxvRb_LE-rPpiBhElzTt76N9cL_NEr02v6DAaepq5OIs7DuR9FZloXrmDC3Oze1vUQoLhdRUUN9yRx1RbYUD79-Z6M5qWVZ3xZ9_p1He8ksnD9EDF1Di4_rDD9CeKh6hA6eyFX7vcKU_PEa_puxnucaj5vqUCi8K7HBBl_hPHgwuNb4Y9ienV3hU1slaSuJZDcBqB42ZhVfA9VY-Hrk8dmw2dfF31epkhcRfYGyB3eHQE3R5Mr4YTXx3DYMvsphs_DCRXApOBmHOB4E5tos1BxknRAgd5iJQAScRl2Ekk1BLHqtYcE00hHJEM_CMT1GnAO4fIpxnKpMBDwc6ssaD5YEkPI1jqQQEQsRDfiMNuqrRNqg9cstglVLzkxpBUidID300IqPgHNRasA01YNm7P-YXBVlEoxSCGiAeGsHuXmxo7YNyfU3d9KIEFubg2KOYsAHR8KWMRaYWmUgwJ5JEHnplpgWtq1R35oEekzjPDJR-5qE3lsKAaxQme-eabauKnn69-geib-ctoneOSJcwwQRzFRPAAAPa1aI8alGCiRCt7kMziRsWVhRixigBW56EMLKZ2Hd3v951m5eajLxClVtLExNCksHAQ89qPdhxtlEuD2UtDWmxvt0Dqm6xzZ1qP__vkS_QfYhpE4vFGRyhzma9VS8hbtzwLliLeQZtPgpNe_Kpi-4Nx2ez867diYF2SvKutSa_Affac38 |
| link.rule.ids | 230,314,727,780,784,864,885,2102,2221,12056,12223,12765,21388,24318,27924,27925,31719,31720,33266,33267,33373,33374,33744,33745,43310,43579,43600,43805,53791,53793,73745,74014,74035,74302 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Jb9NAFB5BOMAFUbYaCh0QEovkxst4O6E2apVAUhB0u41mLUWVHeLkL_C7ec-euDWqEIccnPfGst4-M2--IeRNqlWqTJj7NmfSZ5m0vhAy85mIrMilkSzGg8Kzw3R8zD6dJWduwa12bZXrmNgEal0pXCMfQpqLEjC_JPw4_-XjrVG4u-qu0LhN7kDaz9Cq81HX4gG-nKbuuFychUOnnZ15VZod3E6LEQzyWjoaqHqlHHh_F6IH88uqvqn-_LuN8lpeOnhA7ruCku62FrBBbpnyIdlwLlvTdw5X-v0j8nsmflYLOlpfn1LTi5I6XNBLetUHQytLj_aG48kJHVVts5bR9GsLwNoM2hcNvAJtl_LpyPWxU1zUpaemRxSlplMYW1K3OfSYHB_sH43GvruGwVdZzJZ-mGiplWRFmMsiwG272ErQccKUsmGuAhNIFkkdRjoJrZaxiZW0zEIpx6yAzPiEDEoQ-SaheWYyHciwsFETPEQeaCbTONZGQSHEPOKvtcHnLdoGb7bcMpiltPLkqD3utOeRD6gyDsnBLJRYcgTL7h7wFwVZxKMUihpg3kPFdi9G3uaPanHOnZ9yBhNzSOxRzETBLHypEBGeRWYawolmkUe20Sx4e0q1Cw98l8V5hlD6mUdeNxwIrlFi9865WNU1n3w5-Q-m7996TG8dk63AwJRwJyZAAAja1ePc6nFCiFA98iYa8VqENb9yJhi5Nuybya86Mr4UO_JKU60anpgxlhSFR562ftBJNkphFp7mqUeynof0RN-nlBc_GmxzhmBNafrs35-1Te6Oj2ZTPp0cfn5O7kERmzTgm8EWGSwXK_MCCsWlfNlEgz_e0GcY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9NAEF5BkBAviHLVUOiCkDgkNz7W1xNqQ6ME2lJBr7fVnqWoskOc_AV-NzP2xq1RhXjIgzOzljX37s5-S8ibVKtUmTD3bc6kzzJpfSFk5jMRWZFLI1mMB4X3D9LJMft8lpy5_qfatVWuYmITqHWlcI18CGkuSsD8knBoXVvE4afxx9kvH2-Qwp1Wd53GbXIHb5lDHP181LV7gF-nqTs6F2fh0Glqa1aVZgu31mIEhryWmgaqXioH5N-F68HssqpvqkX_bqm8lqPGD8h9V1zS7dYa1sgtUz4ka859a_rOYUy_f0R-74uf1ZyOVlep1PSipA4j9JJe9cTQytKjneFkekJHVdu4ZTQ9bMFYm0G7ooFaoO2yPh25nnaKC7z01PSIotR0D8aW1G0UPSbH492j0cR3VzL4KovZwg8TLbWSrAhzWQS4hRdbCfpOmFI2zFVgAskiqcNIJ6HVMjaxkpZZKOuYFZAln5BBCSJfJzTPTKYDGRY2agKJyAPNZBrH2igoiphH_JU2-KxF3uDN9lsGM5ZWnhy1x532PPIBVcYhUZi5EguOwNndA_6iIIt4lEKBA8w7qNjuxcjb_FHNz7nzWc5gkg5JPoqZKJiFLxUiwnPJTENo0SzyyCaaBW9PrHahgm-zOM8QVj_zyOuGA4E2SjTZc7Gsaz79evIfTN-_9ZjeOiZbgYEp4U5PgAAQwKvHudHjhHCheuR1NOKVCGt-5VgwcmXYN5NfdWR8KXbnlaZaNjwxYywpCo88bf2gk2yUwow8zVOPZD0P6Ym-TykvfjQ45wyBm9L02b8_a5PchUDA96YHX56Te1DPJg0OZ7BBBov50ryAmnEhXzbB4A-9uGs9 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Major+Challenges+in+Clinical+Management+of+TB%2FHIV+Coinfected+Patients+in+Eastern+Europe+Compared+with+Western+Europe+and+Latin+America&rft.jtitle=PloS+one&rft.au=Efsen%2C+Anne+Marie+W&rft.au=Schultze%2C+Anna&rft.au=Post%2C+Frank+A&rft.au=Panteleev%2C+Alexander&rft.date=2015-12-30&rft.eissn=1932-6203&rft.volume=10&rft.issue=12&rft.spage=e0145380&rft_id=info:doi/10.1371%2Fjournal.pone.0145380&rft_id=info%3Apmid%2F26716686&rft.externalDocID=26716686 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |